Zydus Lifesciences bags USFDA nod for Bortezomib for Injection to treat cancer
The drug will be manufactured at Zydus Hospira.
Ahmedabad: Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) has recently announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial (USRLD: Velcade).
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma. The medication works by slowing or stopping the growth of cancer cells.
The drug will be manufactured at Zydus Hospira. Velcade has a market size of USD 1,172mn (as per IQVIA MAT Mar'22).
The group now has 331 approvals and has so far filed over 400 ANDAs since the commencement of filing process in FY 2003-04.
Read also: Zydus Lifesciences publishes phase 3 trials of Desidustat in American Journal of Nephrology
Zydus group is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Read also: Zydus Lifesciences bags USFDA nod for Vitamin B12 injection Cyanocobalamin
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd